Yuanbio Venture Capital is a leading healthcare investment firm focusing on early and growth stage companies. Based in Suzhou bioBay, Yuanbio keeps a global vision. Till now, we have built up a portfolio of over 180 companies, covering biotech, medical devices, IVD, and healthcare services fields. The firm has seen great investment returns with 19 of its portfolio companies listed on the STAR, Hong Kong Stock Exchange and Nasdaq. YuanBio has received multiple awards as one of the leading healthcare VCs in China. We have a group of experts experienced in healthcare industry, corporate management and early stage investment. With passion, dedication and expertise, YuanBio strives to become one of the most successful healthcare venture capital firms in China.
Active investor for years. High quality portfolio widely recognized in the industry. Broad media coverage. Portfolio companies frequently selected as the Rising Star of the industry
With bioBay and over 140 portfolio companies, YuanBio has established a network covering biotech, medical devices, IVD and healthcare services.
Value added services to support and guide portfolio companies' growth and development
Members of investment team are equipped with profound scientific knowledge and deep industry experience, guided by a team of senior experts and consultants.
Extensive network and cooperation with industry players, KOLs, institutions and other funds
Rich deal sources, post-investment value added services, industry information and resource sharing
MBA from University of Chicago; PhD in molecular biology from Medical College of Columbia University; Bachelor in Biology from Peking University
MBA from Cornell University (US); Bachelor from Zhongshan University
EMBA from CEIBS; LLM from Peking University; BS in Economics from Beijing Technology and Business University
元生创投被投企业新闻 | 生殖领域专家贝康医疗拟赴港IPO
Suzhou pioneer pharmaceutical get $10000000 Investment: investment Honghui capital
Elon Musk "endorsements" Scanadu Scout complete B round of $35 million in financing, fosun international, tencent, capital investment in broadband
Nature project: fourth fatal cancer of large intestine
JHL Biotech Lists on the Taiwan Emerging Stock Board